Differential Gene Expression In Physiological And Pathological Angiogenesis

  • Published: May 15, 2008
  • Earliest Priority: Nov 09 2006
  • Family: 11
  • Cited Works: 0
  • Cited by: 0
  • Cites: 0
  • Sequences: 234
  • Additional Info: Published Sequence

The full document isn't yet available to us from the patent office, but we've found a related patent (family member) to use for our images and PDF.


Methods of inhibiting pathological angiogenesis in a subject are disclose d. In particular examples, the method includes administering a therapeutical ly effective amount of a composition to a subject wherein the composition in cludes a specific binding agent that preferentially binds to one or more pat hological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat 10), Doppel (prion-PLP), Apelin, Plgf , Ptprn (IA-2), CD109, Ankylosis, and collagen VIII.alpha.1. In additional e xamples, methods to deliver a therapeutic agent to a brain or liver endothel ial cell are also disclosed.


Information currently unavailable.

Family Member PDF
Family Member Preview
These are the images from a related family member, as the full document isn't yet available to us from the patent office.
Document History
  • Publication: May 15, 2008
  • Application: Jun 28, 2007
    CA CA 2669260 A
  • Priority: Jun 28, 2007
    US US 2007/0072395 W
  • Priority: Jan 8, 2007
    US US 87945707 P
  • Priority: Nov 9, 2006
    US US 85806806 P

Download Citation

Sign in to the Lens